Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Ntrust-1: A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects with Autoimmune Disease
Yao, Q. P. (PI), Gabig, T. (CoPI), Jandl, T. (CoPI), Lan, F. (CoPI), Lee, C. (CoPI), Liu, S. (CoPI) & Schuster, M. (CoPI)
05/16/25 → 08/19/26
Project: Research
-
Ntrust-2: A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy in Subjects with Immune-Mediated Diseases
Schuster, M. (PI), Gabig, T. (CoPI), Jandl, T. (CoPI), Lan, F. (CoPI), Lee, C. (CoPI) & Liu, S. (CoPI)
05/5/25 → 03/26/26
Project: Research
-
ICT-8 Efficacy Study of Inecalcitol in Combination with Decitabine in Acute Myeloid Patients Unfit for Standard Chemotherapy
Gabig, T. (CoPI), Lan, F. (CoPI), Schuster, M. (CoPI), Salman, H. (PI) & Kiner-Strachan, B. (CoPI)
10/27/17 → 08/2/19
Project: Research
-
A Phase 1/1b,Multicenter, Open-label, Dose Escalation Study of FT-2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation
Schuster, M. (PI), Gabig, T. (CoPI), Lan, F. (CoPI), Kiner-Strachan, B. (CoPI) & Salman, H. (CoPI)
Forma Therapeutics, Incorporated
10/19/17 → 08/21/19
Project: Research
-
A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study of Pracinostat in Combination with Azacitidine in Patients 18 Years with Newly Diagnosed Acute Myeloid Leukemia unfit for Standard Induction Chemotherapy
Gabig, T. (CoPI), Lan, F. (CoPI), Schuster, M. (CoPI), Salman, H. (PI) & Kiner-Strachan, B. (CoPI)
09/28/17 → 07/23/19
Project: Research
-
Burixafor, a CXCR4 inhibitor with a differentiated kinetics profile: results of a phase 2 study for rapid cell mobilization in multiple myeloma and lymphoma patients undergoing transplant
Sukhtankar, D. D., Cardarelli, P. M., Jalilizeinali, B., Setia, G., Kim, G. Y., Chang, L. W., Tsai, C. Y., Caculitan, N. G. & Schuster, M., Mar 2026, In: Annals of Hematology. 105, 3, 86.Research output: Contribution to journal › Article › peer-review
Open Access -
A Relapsed AML Case Featuring MYC and MECOM Rearrangements
Murgas, K. A., Materum, P., Li, L. Z., Rocha, J., Schuster, M., Ahmed, T. & Tirado, C. A., Sep 2025, In: Diagnostics. 15, 18, 2410.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Randomized Phase III SIERRA Trial of 131I-Apamistamab before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML
Gyurkocza, B., Nath, R., Seropian, S., Choe, H., Litzow, M. R., Abboud, C., Koshy, N., Stiff, P., Tomlinson, B., Abhyankar, S., Foran, J., Hari, P., Chen, G., Al-Kadhimi, Z., Kebriaei, P., Sabloff, M., Orozco, J. J., Jamieson, K., Silverman, M. & Van Besien, K. & 20 others, , Jan 10 2025, In: Journal of Clinical Oncology. 43, 2, p. 201-213 13 p.Research output: Contribution to journal › Article › peer-review
Open Access10 Scopus citations -
Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trial
Pardee, T. S., Powell, B. L., Larson, R. A., Maly, J., Keng, M., Foster, M., Choi, E. J., Sill, H., Cluzeau, T., Jeyakumar, D., Frankfurt, O., Patel, P., Schuster, M., Koller, E., Costello, R., Platzbecker, U., Montesinos, P., Vives, S., Nazha, A. & Cook, R. & 4 others, , Jun 2024, In: Blood Neoplasia. 1, 2, 100009.Research output: Contribution to journal › Article › peer-review
Open Access6 Scopus citations -
Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients
Dadwal, S. S., Bansal, R., Schuster, M. W., Yared, J. A., Myers, G. D., Matzko, M., Adnan, S., McNeel, D., Ma, J., Gilmore, S. A., Vasileiou, S., Leen, A. M., Hill, J. A. & Young, J. A. H., Sep 10 2024, In: Blood Advances. 8, 17, p. 4740-4750 11 p.Research output: Contribution to journal › Article › peer-review
Open Access16 Scopus citations